MC
MPM Capital
MPM Capital is a Series A to Series B stage investment firm. It has made 14 investments, with focus areas including Biotech & Life Sciences, Healthcare. 79% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals). Average disclosed round size is $80.8M (across 13 rounds with reported amounts).
Portfolio
14
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
AG
Ansbert Gadicke
Co-Founder and Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 AstronauTx Ltd. | Series A | $61M | Oct 2023 |
 Aktis Oncology | Series A | $84M | Aug 2022 |
 CODA Biotherapeutics | Series B | $28M | Dec 2021 |
 Protego Biopharma | Series A | $51M | Nov 2021 |
| Umoja Biopharma | Series B | $210M | Jun 2021 |
 Orna Therapeutics | Series A | $80M | Feb 2021 |
| Umoja Biopharma | Series A | $53M | Nov 2020 |
| EElevateBio | Series B | $170M | Mar 2020 |
 Werewolf Therapeutics | Series A | $56M | Nov 2019 |
 SiO2 Medical Products | Unknown | — | Nov 2019 |
 Frontier Medicines | Series A | $67M | Jun 2019 |
 TriNetX | Series D | $40M | Mar 2019 |
 Tetherex Pharmaceuticals, Inc. | Series B | $50M | Apr 2018 |
Top Co-Investors
DCVC4 shared
F2 Venture Capital3 shared
Qiming Venture Partners USA3 shared
Deerfield2 shared
Cormorant Asset Management2 shared
Alexandria Venture Investments2 shared
SoftBank Vision Fund2 shared
CaaS Capital2 shared
Novartis Venture Fund2 shared
Merck Global Health Innovation Fund1 shared
RA Capital Management1 shared
Versant Ventures1 shared
Silicon Valley Bank1 shared
Double Point Ventures1 shared
ARK Invest1 shared
RTW Investments1 shared
K2 HealthVentures1 shared
Dementia Discovery Fund1 shared
Bristol Myers Squibb1 shared
EQT Life Sciences1 shared
Last updated: 16 April 2026